Xencor (NASDAQ:XNCR) Stock Price Down 3.8% – What’s Next?

Xencor, Inc. (NASDAQ:XNCR)’s share price fell 3.8% on Friday . The company traded as low as $19.46 and last traded at $19.27. 173,302 shares changed hands during trading, a decline of 67% from the average session volume of 530,695 shares. The stock had previously closed at $20.03.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. Wedbush reissued an “outperform” rating and issued a $38.00 price objective on shares of Xencor in a research note on Thursday, November 7th. Wells Fargo & Company started coverage on Xencor in a report on Thursday, December 12th. They issued an “overweight” rating and a $37.00 target price on the stock. JPMorgan Chase & Co. boosted their price target on Xencor from $27.00 to $28.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Royal Bank of Canada upped their price objective on Xencor from $31.00 to $34.00 and gave the stock an “outperform” rating in a research report on Thursday, September 26th. Finally, Piper Sandler upgraded Xencor from a “neutral” rating to an “overweight” rating and lifted their target price for the company from $20.00 to $30.00 in a research report on Monday, December 2nd. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Xencor presently has an average rating of “Buy” and an average price target of $36.56.

Xencor Stock Performance

The business has a 50-day moving average of $23.90 and a two-hundred day moving average of $21.02. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 0.01.

Xencor (NASDAQ:XNCR) last released its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, topping the consensus estimate of ($0.98) by $0.27. The company had revenue of $10.70 million for the quarter, compared to analysts’ expectations of $14.59 million. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The business’s quarterly revenue was down 81.9% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.40) earnings per share. Equities research analysts expect that Xencor, Inc. will post -3.68 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, VP John R. Desjarlais sold 68,684 shares of the stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $23.48, for a total value of $1,612,700.32. Following the completion of the sale, the vice president now owns 200,104 shares of the company’s stock, valued at approximately $4,698,441.92. This represents a 25.55 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Alan Bruce Montgomery sold 1,421 shares of Xencor stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $27.03, for a total value of $38,409.63. Following the completion of the transaction, the director now directly owns 9,140 shares in the company, valued at approximately $247,054.20. This represents a 13.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 136,050 shares of company stock valued at $3,277,609 in the last ninety days. 5.23% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in XNCR. Quarry LP bought a new stake in shares of Xencor in the 2nd quarter valued at $36,000. GAMMA Investing LLC lifted its holdings in Xencor by 31.0% in the fourth quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company’s stock valued at $49,000 after buying an additional 508 shares during the period. KBC Group NV boosted its position in Xencor by 63.5% during the third quarter. KBC Group NV now owns 3,123 shares of the biopharmaceutical company’s stock valued at $63,000 after acquiring an additional 1,213 shares during the last quarter. Rockefeller Capital Management L.P. acquired a new stake in Xencor during the 3rd quarter worth about $205,000. Finally, XTX Topco Ltd acquired a new position in shares of Xencor in the 2nd quarter valued at about $196,000.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.